Ipsen decided to temporarily pause dosing in the company’s palovarotene extension studies for patients with fibrodysplasia ossificans progressiva following a recommendation from an Independent Data Monitoring Committee.

Roche company Genentech announced that the Phase III IMvigor010 trial of Tecentriq as a post-surgery monotherapy did not hit the primary endpoint in muscle-invasive urothelial cancer (MIUC).

Investigators at the Case Western Reserve University School of Medicine identified a previously unknown gene and the resultant protein that may potentially slow the progress of Alzheimer’s disease.

Roche company Genentech announced positive top-line results from the pivotal Part 2 of the FIREFISH study looking at risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA).

Researchers at Cardiff University in the UK have essentially identified a new T-cell and its receptor that can search out and kill a broad range of cancer cells.

Nearly 1.6 billion people worldwide suffer from anemia, and for the first time new research points to how resistance emerges to the drug dexamethasone used to treat the devastating inherited form of anemia known as Diamond Blackfan anemia (DBA).

Indianapolis-based Eli Lilly is adding 462 new jobs in Durham County, North Carolina over five years.

Since completing the acquisition of Shire plc in January 2019, which created one of the largest drug developers focused on rare diseases, Takeda Pharmaceutical Co. has strived to transform itself into becoming a front-runner in multiple areas including cell and gene therapies.

BeiGene Ltd.’s cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.

The U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) generated an evenly split vote on whether to recommend approval of Durect Corporation’s Posimir.